[an error occurred while processing this directive]
Skip to Main Content

Latest News

Advertisement
Advertise Here
February 28, 2011

Merck Sells Biomanufacturing Network To Fujifilm

Biopharmaceuticals: Contract manufacturing operations to transfer to industry newcomer

Ann Thayer

  • Print this article
  • Email the editor

Latest News



October 28, 2011

Speedy Homemade-Explosive Detector

Forensic Chemistry: A new method could increase the number of explosives detected by airport screeners.

Solar Panel Makers Cry Foul

Trade: U.S. companies complain of market dumping by China.

Novartis To Cut 2,000 Jobs

Layoffs follow similar moves by Amgen, AstraZeneca.

Nations Break Impasse On Waste

Environment: Ban to halt export of hazardous waste to developing world.

New Leader For Lawrence Livermore

Penrose (Parney) Albright will direct DOE national lab.

Hair Reveals Source Of People's Exposure To Mercury

Toxic Exposure: Mercury isotopes in human hair illuminate dietary and industrial sources.

Why The Long Fat?

Cancer Biochemistry: Mass spectrometry follows the metabolism of very long fatty acids in cancer cells.

Text Size A A

Just over a year after creating it, Merck & Co. will sell its Merck Biomanufacturing Network to Fujifilm, the Japanese photography and imaging company. Merck will become a "key customer" of Fujifilm, according to the companies.

Fujifilm, which faces a declining photography market, already sells instruments and other technologies to the life sciences and medical sectors. In 2008, it entered the pharmaceutical business by acquiring Japan's Toyama Chemical. Now, the deal with Merck marks its entry into biopharmaceutical contract manufacturing.

"This acquisition provides an important addition to our pharmaceutical business with diverse capabilities and technical expertise in the production of protein therapeutics," Fujifilm CEO Shigetaka Komori said in announcing the deal on Feb. 28.

Under the agreement, Fujifilm will purchase Merck's MSD Biologics and Diosynth subsidiaries. MSD Biologics operates a facility in Billingham, England. Diosynth, which was acquired through Merck's 2009 purchase of Schering-Plough, has a plant in Research Triangle Park, N.C. The purchase includes manufacturing contracts, business support operations, and a technical workforce.

The two operations have a long history in the custom manufacturing arena. Opened in 1995, the North Carolina facility was part of Covance, spun off by Corning in 1996 and acquired by AkzoNobel's Diosynth unit in 2001. Schering-Plough acquired Diosynth in 2007.

Similarly, Zeneca Specialties opened the Billingham site in 1997. In 1999, after a management-buyout, the specialties business became Avecia. In late 2009, Merck agreed to purchase Avecia's biologics business, including the Billingham site.

Merck created the BioManufacturing Network in 2010 by combining the two operations. They produce recombinant proteins, vaccines, and monoclonal antibodies for drug industry customers. Since late last year, Merck has announced four new commercial production agreements for partners.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!